tradingkey.logo

PharmaCyte Biotech Inc

PMCB
View Detailed Chart
0.741USD
+0.041+5.89%
Close 02/06, 16:00ETQuotes delayed by 15 min
5.04MMarket Cap
LossP/E TTM

PharmaCyte Biotech Inc

0.741
+0.041+5.89%
Intraday
1m
30m
1h
D
W
M
D

Today

+5.89%

5 Days

-9.50%

1 Month

-3.99%

6 Months

-12.80%

Year to Date

+2.38%

1 Year

-53.38%

View Detailed Chart

Key Insights

PharmaCyte Biotech Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 213 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

PharmaCyte Biotech Inc's Score

Industry at a Glance

Industry Ranking
213 / 392
Overall Ranking
428 / 4521
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

PharmaCyte Biotech Inc Highlights

StrengthsRisks
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is -0.66, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 434.85K shares, decreasing 46.71% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 80.00K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 4.02.

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

PharmaCyte Biotech Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

PharmaCyte Biotech Inc Info

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Ticker SymbolPMCB
CompanyPharmaCyte Biotech Inc
CEOSilverman (Joshua N)
Websitehttps://pharmacyte.com/
KeyAI